Cardiovascular Therapeutics

Review Article

Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis

Table 4

Input data for the NMA of the risk of amputation.


Study	Treatments	Event rate (%)	HR [95% CI]	Analysis
				Base case	Sensitivity

MIRROR [24]	CLO+ASA	6/35 (17.1%)	0.94 [0.30, 2.91]	✔	✔
	ASA	6/33 (18.2%)	Reference
CASPAR [19]	CLO+ASA	31/425 (7.3%)	0.68 [0.43, 1.08]	✔	✔
	ASA	45/426 (10.6%)	Reference
VOYAGER PAD [14]	RIV+ASA	103/3286 (3.1%)	0.89 [0.68, 1.16]	✔	✔
	ASA	115/3278 (3.5%)	Reference
BOA [17]	VKA	100/1326 (7.5%)	0.90 [0.69, 1.19]	✗	✔
	ASA	110/1324 (8.3%)	Reference
CHARISMA [21]	CLO+ASA	12/1545 (0.8%)	0.71 [0.34, 1.48]	❌	✔
	ASA	17/1551 (1.1%)	Reference
COMPASS [16]	RIV+ASA	20/2492 (0.8%)	0.53 [0.31, 0.91]	❌	✔
	ASA	38/2504 (1.5%)	Reference
WAVE [25]	VKA+ASA	8/1080 (0.7%)	0.67 [0.27, 1.63]	❌	✔
	ASA	12/1081 (1.1%)	Reference

✔: study eligible for the analysis; ❌: study ineligible for the analysis. ASA: acetylsalicylic acid; CLO: clopidogrel; RIV: rivaroxaban; VKA: vitamin K antagonist.